TrialBMC cancer2025

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial.

Kugeluke Yalikun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.